抗ＰＤ－Ｌ１抗體及其作為治療及診斷之用途

• 收藏
• 分享

专利权人:

BEIGENE; LTD

发明人:

LI, KANG,李康,SONG, JING,宋竞,宋競,ZHANG, TONG,张彤,張彤,LI, YUCHENG,李渝成,REN, ZHIYING,任智颖,任智穎,KANG, YANSHEN,康延申

申请号：

TW104121364

公开号：

TW201625681A

申请日:

2015.07.01

申请国别(地区):

TW

年份:

2016

代理人:

摘要：

Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.本發明提供特異性結合至計畫性死亡-1(PD1、Pdcd-1或CD279)配體(PD-L1)並抑制免疫細胞中PD-L1介導的細胞傳訊及活性的抗體，結合至配體結合所需要之一組胺基酸殘基的抗體，及該等抗體治療或診斷由PD-L1介導功能所調變的癌症、傳染性疾病或其他病理學病症之用途。

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/